We observed that the number of junctions not found in core normals per patient was comparable for patients with and without splicing factor-associated mutations across all cancer types, with the exception of breast adenocarcinoma (Supplementary Figure S1F and S1G). This evidence concerns the gene SLU7 and breast adenocarcinoma.